Hon. Ron Philips – Managing Director
Since leaving politics in 1999 Ron has developed a successful consulting business in the Health and Aged Care Industry. Ron was co-owner and Managing Director of the Sydney Breast Cancer centre prior to the sale to Healthscope. Ron is founder shareholder and part owner of BCAL Diagnostics Pty Ltd. He is also Chair of the Sydney Local Health District.
Dr. Dharmica Mistry (PhD) – Chief Scientist
Dr. Dharmica Mistry is the Company’s senior scientist. Dharmica holds a BSc (Hons) from Sydney University, majoring in Microbiology, and has completed a PhD at Macquarie University that was based on examining the association of lipids in hair and serum with the presence of breast cancer. Dharmica is an inventor on one of the Company’s founding patents and manages the scientific operations of the company. Dharmica has worked in the Australian biotechnology industry since 2007.
In 2015 Dharmica graduated with a distinction from the NSW Health Medical Devices Commercialisation Training Program. In 2016 Dharmica was the recipient of the “NSW Young Woman of the Year” award for which she was nominated by the Minister of Health, Jillian Skinner. She was also announced as Young Executive of the Year (2016) in Australia by the Australian Financial Review (AFR) Boss Magazine.
Jayne Shaw – Chairman
Jayne Shaw trained as a Registered Nurse in the UK, on arrival in Australia she became a Director of Nursing and Chief Executive Officer of two private hospitals. Following this she established an Australian and International consulting business which was sold to Healthsouth a large US Healthcare company. After this she became the Co-founder of Vision Group an Opthalmic Doctor equity consolidation model which was successfully listed on the ASX.
Jayne joined a number of private Healthcare Boards involved with specialist consolidation including Cardiology, Orthopaedics, and Women’s Health she continued to work with Private Equity firms on local and International Healthcare transactions. Jayne, together with Ron Phillips was a co-owner of Sydney Breast Clinic and a co-founder of BCAL Diagnostics.Current Board positions are Critical Group – Heatley’s Industrial Supplies, The Woolcock Research Institute, and The Hareda Foundation established to invest in Women’s Health Initiatives.
Dr. Peter French MBA, PhD – Director & Scientific Advisor
Peter is a Scientific Consultant for BCAL Diagnostics Pty Ltd. Peter is the Chief Executive Officer and Chief Scientific Officer of publicly listed (ASX:BLT) gene silencing company Benitec Ltd.
Peter is a cell and molecular biologist who has extensive experience in both basic and clinical medical research and commercialisation of biological intellectual property. Peter has held several senior roles in Australia’s biotechnology industry, including as founder and director of the stem cell storage company Cryosite Ltd (ASX:CTE).
Johnathan Trollip – Director
Jonathan Trollip has 30 years legal and commercial experience in the international financial sector. He is currently a Principal and Director of Sydney based structured finance group Meridian International Capital Limited with whom he has been for the past 20 years. Prior to that, Jonathan was a Partner with Herbert Smith Freehills (previously Freehills) whom he joined after qualifying and working as a lawyer in London.
Jonathan has post graduate degrees in economics and law, is a Fellow of the Australian Institute of Company Directors, has been admitted to practice as a solicitor in England and Australia and holds a current solicitor’s practising certificate.
Jonathan is currently Chairman of ASX listed companies Future Generation Investment Fund Limited and Global Value Fund Limited.
Carl Stubbings – Head of Commercialisation
Carl Stubbings is a highly qualified senior executive with over thirty years experience in biotechnology and medical diagnostics. His background includes manufacturing, administration, and extensive international sales and marketing expertise in North America, Latin America, Asia Pacific and Europe.
Prior positions include:
• Chief Business Officer Benitec Biopharma (ASX: BLT)
• Vice President Sales & Marketing for Focus Diagnostics a subsidiary of Quest Diagnostics (NASDAQ; DGX)
• Senior Vice President Panbio Ltd (USA)
• Current board appointments include Analytica Medical (ASX: ALT), Sienna Cancer Diagnostics Unlisted Public Company (SCDU) and Otakaro Pathways New Zealand based Private Company.
In his role at Panbio (USA) and Focus Diagnostics, Carl led the commercialisation of number of medical diagnostic products. These achievements include the development and first FDA cleared test for West Nile Virus (Panbio USA). First FDA cleared molecular test for H1N1 (Influenza) and range of other ‘first in class’ molecular tests for viral diseases (Focus Diagnostics).
Prior to moving back to Australia, Carl and his family had lived and worked in the USA for more than 12 years.
Carl holds a B.App.Sc. from the Queensland University of Technology; he holds dual Australian and US citizenship.